Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study
Authors
Rini, BIPlimack, ER
Stus, V
Gafanov, R
Hawkins, Robert E
Nosov, D
Pouliot, F
Soulieres, D
Melichar, B
Vynnychenko, I
Azevedo, SJ
Borchiellini, D
McDermott, RS
Bedke, J
Tamada, S
Wan, SY
Perini, RF
Chen, M
Atkins, MB
Powles, T
Affiliation
Cleveland Clinic Taussig Cancer Institute, Cleveland, OHIssue Date
2019
Metadata
Show full item recordCitation
Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study. J Clin Oncol. 2019;37(15_suppl):4500-.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2019.37.15_suppl.4500Additional Links
https://dx.doi.org/10.1200/JCO.2019.37.15_suppl.4500Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2019.37.15_suppl.4500